• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

De­nali un­veil proof-of-con­cept da­ta for brain de­liv­ery tech in rare dis­ease, with eyes on much big­ger in­di­ca­tions

5 years ago
R&D

George Church and an en­tre­pre­neur­ial post­doc join the hunt for AAV 2.0 with a new vec­tor-cloak­ing tech­nol­o­gy

5 years ago
Startups
Cell/Gene Tx

Roche touts less oner­ous sched­ule for its in-the-eye in­jec­tion faricimab, hop­ing to sweet­en the sales pitch over ...

5 years ago
R&D

Covid-19 roundup: Fau­ci says first graders could have ac­cess to vac­cine by Sep­tem­ber — re­port; EMA be­gins rolling ...

5 years ago
Coronavirus

Eli Lil­ly strips oust­ed CFO Josh Smi­ley of $24M in pay af­ter 'i­nap­pro­pri­ate mes­sages' scan­dal

5 years ago
People

Am­gen los­es ap­peal in patent suit against Sanofi/Re­gen­eron’s Pralu­ent. It’s a bum­mer for Bris­tol My­ers Squibb and ...

5 years ago
Pharma

Am­i­cus shares slammed as lead PhI­II drug fails a key head-to-head test for Pompe dis­ease — but the CEO still ...

5 years ago
R&D
FDA+

Re­gen­eron an­ti­body earns nod for rare cho­les­terol dis­or­der — but it ain't cheap

5 years ago
FDA+

Wad­ing deep­er in­to tar­get dis­cov­ery and val­i­da­tion, Im­mu­nai bags $60M to beef up both AI al­go­rithms and lab bench­es

5 years ago
Financing
AI

Vi­gene Bio­sciences goes big on Mary­land vi­ral vec­tor ex­pan­sion as it rides high on Al­tim­mune vac­cine deal

5 years ago
Manufacturing

End­points Man­u­fac­tur­ing: Lon­za drops in­gre­di­ents biz in $4.7B sale; Touch­light's 'dog­gy­boneD­NA' looks to rewrite ...

5 years ago
Manufacturing

Ger­many's Rentschler looks to build UK foot­print with five-year in­vest­ment in cell and gene ther­a­pies

5 years ago
Deals
Manufacturing

Quo­tient, buoyed by Covid-19 work, buys Ar­ci­no­va in ef­fort to build end-to-end CD­MO brand

5 years ago
Deals
Manufacturing

With crossover round in its pock­et, syn­thet­ic lethal­i­ty-fo­cused Cyteir Ther­a­peu­tics eyes a jump on­to Nas­daq

5 years ago
Financing

Ex­sci­en­tia to col­lab­o­rate with Ox­ford's Alzheimer's cen­ter; Dana-Far­ber en­lists Reper­toire for head and neck can­cer

5 years ago
News Briefing

Bris­tol My­ers takes next big gam­ble on I/O fron­tier, pledg­ing near­ly $1.4B on Texas fir­m's tu­mor tox­ins

5 years ago
Deals

Dyno sketch­es tens of thou­sands of vi­able next-gen AAV cap­sids with the help of ma­chine learn­ing — pa­per

5 years ago
AI
Cell/Gene Tx

AC Im­mune has 're­mark­able' Alzheimer's vac­cine da­ta. Just don't ask to see them

5 years ago
R&D

No­var­tis' San­doz splurges on a trio of GSK an­tibi­otics, dou­bling down with a $500M bet on a field strug­gling to ...

5 years ago
Deals

All in on ide-cel, Bris­tol My­ers Squibb writes off $470M as sec­ond BC­MA CAR-T is eject­ed from the pipeline

5 years ago
R&D

Fre­se­nius Kabi pays $50 mil­lion to set­tle crim­i­nal charges

5 years ago
FDA+
Manufacturing

Ver­sant spin­out lands $80M to go 'much broad­er' than the old Roche part­ner­ship that birthed it

5 years ago
Financing

In­di­a's TCG launch­es new CD­MO arm state­side to meet the call for 'Amer­i­can-made' pan­dem­ic drugs

5 years ago
Manufacturing

No­vo Nordisk's block­buster di­a­betes drug blows the doors off in obe­si­ty, prov­ing high­ly ef­fec­tive in dri­ving weight ...

5 years ago
R&D
First page Previous page 735736737738739740741 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times